ArcherDX Acquires Baby Genes, Genetic-Based Personalized Medicine Company
BOULDER, Colo., January 30, 2019 / PRNewswire / – ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, is pleased to announce the acquisition of Baby Genes, Inc, a privately held CLIA certified and CAP accredited laboratory focused on empowering individuals to take charge of their health through genetic knowledge. Baby Genes will continue to operate as a wholly owned subsidiary under the name ArcherDX Clinical Services, Inc. and the company will continue to market the existing line of newborn and carrier genetic testing services under the Baby Genes brand. ™.
Baby Genes Acquisition Adds Valuable New Assets to ArcherDX, Including CLIA Certified and CAP Accredited Genetics Lab at Golden, Colorado with a menu of tests including an additional newborn screening panel that interrogates over 100 genes spanning over 72 clinically exploitable hereditary conditions as well as pre-defined carrier screening tests that include complete gene sequencing for cystic fibrosis (CF), spinal muscular atrophy (SMA) and fragile X syndrome. In addition, the laboratory also offers physicians personalized confirmation and reflex genetic testing services.
“We have a long, positive working relationship with Baby Genes and from day one we have seen a natural alignment between the two organizations regarding our shared commitment to accelerate the adoption and application of personalized health,” said Jason myers, co-founder and CEO of ArcherDX. “Archer’s mission is to democratize personalized medicine and the decentralization of testing is fundamentally important to the success of personalized medicine because of the efficiency and accuracy achieved when testing is done locally. a CLIA / CAP accredited laboratory enables our mission, not by centralizing testing, rather to enable us to expand our capabilities in the genetic testing market, improve our ability to understand and anticipate the needs of our clients – by especially those looking to implement the NGS for the first time or expand the capabilities of the NGS, and improve our capacity for co-development of biopharmaceutical partners. ”
As a result of the transaction, ArcherDX Clinical Services, Inc. will leverage existing ArcherDX research and development capabilities in Boulder, Colorado while all business profiling services for both companies will be bundled into the Golden, Colorado laboratory. Ultimately, Richard Sjögren, previously co-founder and CEO of Baby Genes, will join the ArcherDX leadership team as vice president of operations.
“We look forward to working with the extended ArcherDX team to expand the reach and availability of our proactive genetic health testing,” said Richard Sjögren. “We see enormous growth opportunities ahead as we continue to partner with innovative scientists, healthcare professionals and proactive individuals to make a difference in extending and improving quality of life. ”
ArcherDX advances molecular pathology with a robust technological platform for the detection of genetic mutations by next-generation sequencing. By combining the patented Anchored Multiplexed PCR (AMP ™) chemistry in an easy-to-use freeze-dried format and powerful bioinformatics software, the Archer® platform dramatically improves the identification and discovery of genetic mutations. ArcherDX provides oncology-focused research products and seeks regulatory approval for several companion diagnostic tests. ArcherDX also recently received Breakthrough Device designation with a companion diagnostic test for liquid and tissue biopsy samples by the United States Food and Drug Administration.